Prescribing Patterns for Initiation of Ustekinumab in Crohn Disease
Prescribing patterns among patients treated with ustekinumab for Crohn disease were presented at the 2019 AIBD Annual Meeting.
Crohn Disease
CROHN DISEASE
Latest Articles
Reasons for Certolizumab Use Examined in Patients With Crohn Disease
To better understand the real-world prescribing patterns of certolizumab, researchers collected data from a large multicenter gastroenterology private practice dating back to 2008.
Ontamalimab Induces Clinical, Symptomatic Remission in Ulcerative Colitis Patients
Treatment with ontamalimab was associated with both clinical and symptomatic remission in patients with ulcerative colitis (UC), according to data presented at the 2019 AIBD Annual Meeting held in Orlando, Florida.
Mental Health Services Underutilized in Pediatric IBD Patients
Inflammatory bowel disease (IBD) diagnosis appears to be associated with high levels of anxiety and depression in children, however, new study findings presented at the 2019 AIBD Annual Meeting suggest that many of these patients may not be receiving appropriate mental health services.
ED Visits, Hospitalization Trends Examined in Patients With IBD
Trends in the utilization of emergency department (ED) care and hospitalization among patients with inflammatory bowel disease (IBD) were investigated in a new study.
Safety of IV Iron Products Compared in Patients With IBD
The safety profiles of various IV iron products were compared in a study involving patients with inflammatory bowel disease IBD being treated for iron deficiency anemia.
Effects of Adalimumab, Infliximab in Biologic-Naive IBD Patients
Treatment with adalimumab or infliximab in biologic-naive patients with Crohn disease or ulcerative colitis demonstrated similar outcomes on Patient-Reported Outcomes Measurement Information System measures and rates of corticosteroid-free remission.
PPI Use and Periodontal Disease: What’s the Link?
“The data indicate that more conservative periodontal therapy might initially be considered for IBD patients with advanced periodontal disease for whom PPI are prescribed as a component of their IBD treatment,” the authors concluded.
Timing of Biologic/JAK Inhibitor Treatment Initiation in IBD Patients Examined
According to new research over 1 in 5 patients with inflammatory bowel disease (IBD) should have started treatment with an advanced systemic therapy earlier in their disease.
Combination Biologics or Small Molecules vs Biologic Monotherapy in IBD
Combination biologic therapy may be an effective treatment option for patients with inflammatory bowel disease (IBD) who are refractory or have a concomitant autoimmune disease that is inadequately controlled by biologic monotherapy.
Biosimilar BI 695501 Comparable to Reference Product in Crohn Disease
Biosimilar BI 695501 demonstrated non-inferior efficacy and similar safety profile compared with the reference product adalimumab in patients with active Crohn disease.
Vedolizumab Shows Long-Term Efficacy and Safety Data in Patients with Active UC and CD
Vedolizumab demonstrated long-term effectiveness and favorable safety profile in patients with moderately-to-severely active ulcerative colitis and Crohn Disease.
Proactive Monitoring of Adalimumab Trough Concentration Helps Children With Crohn Disease Achieve Remission
Proactive monitoring of adalimumab trough concentrations in children was associated with higher corticosteroid-free sustained remission and biologic remission rates compared with reactive monitoring in pediatric patients with Crohn disease.
Competition in Inflammatory Bowel Disease Clinical Trials
IBD clinical trials have become increasingly complex as more specific clinical endpoints have gathered support within the academic arena. There has also been an emphasis on long-term extension safety and efficacy data which can further complicate recruitment.
Low-FODMAP Diet Appears to Improve Symptoms in Inflammatory Bowel Disease
The abundance of particular gut microbes believed to regulate immune response were reduced in fecal samples from participants on the low-FODMAP diet compared with those on the control diet.
Changes in Gut Microbiome Associated With Biologic Therapy in Inflammatory Bowel Disease
Prospective studies are needed to determine what changes are significantly associated with treatment, whether these changes are causes or effects of response, and whether the composition of the intestinal microbiome can be used to select treatments for patients with IBD.
Disease Activity, Functional Impairment in Axial Spondyloarthritis With Psoriasis or Inflammatory Bowel Disease
Researchers assessed the effect of uveitis, psoriasis, and inflammatory bowel disease on disease activity and functional status in a population-based cohort of patients with axial spondyloarthritis.
ACR: Few Serious Infections Seen in Infants Exposed to non-TNFis, Tofacitinib
For offspring of mothers with inflammatory disease, those exposed to tofacitinib or non-tumor necrosis factor inhibitor (TNFi) biologics in utero have few serious infections.
Proactive TDM May Lead to Better Outcomes in IBD Compared With Reactive TDM
Guidelines and common practice support the role of reactive-based dose optimization at the time of loss of response in patients with IBD being treated with biologics.
Chronic Axial Pain Prevalent in Inflammatory Bowel Disease
This study evaluated previously unreported data from the NHANES 2009-2010 and NHANES 2 (1976-1980) questionnaires that were used to compare axial pain rates among patients with and without inflammatory bowel disease.
Want to read more?
Please login or register first to view this content.